Opinion|Videos|March 6, 2024
Real-World Insights: Factor vs Emicizumab in Hemophilia A
Steven W. Pipe, MD, discusses real-world evidence comparing factor replacement to emicizumab in hemophilia A, exploring efficacy, adherence, and cost considerations.
Episodes in this series
This is a video synopsis/summary of an Insights featuring Steven W. Pipe, MD.
Pipe delves into the real-world evidence surrounding factor replacement therapy and emicizumab in treating hemophilia A. With a robust clinical trial program involving hundreds of patients, the discussion extends to over 2300 individuals in real-world settings, shedding light on adherence, efficacy, and outcomes. The data suggests that patients on emicizumab prophylaxis consistently maintain low annualized bleed rates, often ranging from zero to 2, with a significant proportion achieving zero treated bleeds annually. Pipe explores switching studies, acknowledging mixed results, especially in regions with varying prophylaxis approaches. While annualized bleed rates may not always show a clear differentiator, patient preferences, quality of life measures, and activity levels strongly favor emicizumab due to its regimen ease, subcutaneous delivery, and steady-state levels. The interview also touches on cost considerations, noting that in the US, emicizumab's pricing might result in higher annualized costs compared to standard half-life agents. The comprehensive analysis underscores the importance of real-world evidence in understanding the practical implications and patient-centric benefits of these evolving hemophilia A therapies.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Related to this article
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
These findings demonstrate substantial but variable use of community care consultations for specialty care among patients with diabetic foot ulcers within the Veterans Health Administration.
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
Trending on AJMC
1
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Switching to Subcutaneous Ocrelizumab for MS Could Free 883 Chair Hours in a Year
4
Why 4 in 5 Eligible Adults Miss Lung Cancer Screening
5